Index

Note: Page numbers of article titles are in boldface type.

A

Abciximab (ReoPro), 499–500
Acetylsalicylic acid, 497–498
Acidosis, in catastrophic bleeding, homeostatic
resuscitation for, 561
Acquired hemophilia, in oral and maxillofacial surgery
patients, 485–486
Acquired thrombocytopenias, in oral and
maxillofacial surgery patients, 478–479
Activated partial thromboplastin time, in preoperative
assessment, 467
Adenosine diphosphate receptor inhibitors, 498–499
clopidogrel (Plavix), 498–499
prasugrel (Effient), 499
ticagrelor (Brilinta), 499
ticlopidine (Ticlid), 498
Adhesives, tissue, topical hemostasis with, 527
Alginate dressings, topical hemostasis with, 526
Alkylene oxide copolymer, topical hemostasis with,
527
Andexanet alfa, reversal of direct oral anticoagulants
with, 518–519
Angiography, in bleeding disorders, 536
Anti-inhibitor coagulant complex, transfusion of, 548
Antibiotics, effects on coagulation and interactions
with anticoagulants, 466
Anticoagulants. See also Direct oral anticoagulants.
administration in patients presenting for surgery,
446–447
apixaban (Eliquis), 447
coumadin, 446
dabigatran (Pradaxa), 446
edoxaban (Savaysa), 447
fondaparinux (Arixtra), 446
Jantoven, 446
low-molecular-weight heparin, 446
Marevan, 446
rivaroxaban (Xarelto), 446
unfractionated heparin, 446
warfarin, 446
perioperative management of patients on,
447–454
in emergency surgery, 454
fondaparinux, 452
new oral agents, 452–454
warfarin, 448–452
Antifibrinolytics, for topical hemostasis, 525
Antiplatelet medications, and herbal medications,
444–445
in oral and maxillofacial surgery patients, 497–506
adenosine diphosphate receptor inhibitors,
498–499
clopidogrel (Plavix), 498–499
prasugrel (Effient), 499
ticagrelor (Brilinta), 499
ticlopidine (Ticlid), 498
adenosine reuptake inhibitors, 499
dipyridamole (Persantine), 499
glycoproteins IIb/IIIa inhibitors, 499–500
abciximab (ReoPro), 499–500
eptifibatide (Integrillin), 500
tirofiban (Aggrastat), 500
hemorrhagic versus thrombotic risks, 501–502
information for surgeons, 502–503
intravenous antiplatelets, 499–500
phosphodiesterase inhibitors, 499
cilostazol (Pletal), 499
therapy with, 500
thromboxane/cyclooxygenase inhibitor,
497–498
aspirin, 497–498
withdrawal, 500–501
Antithrombin, in hypercoagulable states, 491–495
Apixaban (Eliquis), administration in patients
presenting for surgery, 447, 515–521
reversal of, 518–519
Arixtra. See Fondaparinux.
Aspirin, 497–498
Atrial fibrillation, perioperative management of
patients on warfarin for, 448–450

B

Biological hemostats, topical, 525–526
antifibrinolytics, 525
naturally occurring procoagulants, 525–526
alginate dressings, 526
chitin/chitosan dressings, 526
hemocoagulants, 525–526
mineral zeolite, 526
topical thrombin, 525
Bivalirudin, administration in patients presenting for
surgery, 445
Bleeding diathesis, 524
Bleeding disorders. See Coagulopathy.
Bleeding time, in preoperative assessment, 466
Bleeding, catastrophic. See Catastrophic bleeding.
Blood products, 543–552

http://dx.doi.org/10.1016/S1042-3699(16)30085-1
1042-3699/16/$ – see front matter
Index

Blood (continued)
  anti-inhibitor coagulant complex, 548
  cryoprecipitate, 545–546
  Factor IX, 547–548
  Factor VIIA, 546
  Factor VIII, 547
  Factor XIII, 546–547
  Factor XIII-A subunit, 549
  fibrinogen concentrate, 548–549
  fresh frozen plasma, 545
  plasma, 545
  platelets, 544–545
  prothrombin complex concentrates, 546
  red blood cells, 543–544
  transfusion complications, 549–550
    acute hemolytic reactions, 549
    allergic reactions, 550
    bacterial contamination and endotoxemia, 549
    nonhemolytic febrile reactions, 549
    transfusion-related acute lung injury, 549–550
    volume overload, 549
Bone marrow failure, oral and maxillofacial surgery in patients with, 464
Bone wax, topical hemostasis with, 527
Brilinta. See Ticagrelor.

C
Catastrophic bleeding, damage control resuscitation for, 533–568
  hemodynamic resuscitation, 556–558
  hemorrhage-associated coagulopathy, 555–556
  hemorrhagic shock, 554–555
  hemostatic resuscitation, 558–561
    fixed component ratio-directed, 558–559
    goal-directed, 559–560
    pharmacologic adjuncts, 560–561
  homeostatic resuscitation, 561–563
    acidosis, 561
    divalent catastrophic deficiency, 562
    hypothermia, 561–562
    hypoxia, 562
    minimizing ischemia-reperfusion injury, 562–563
Cellulose, oxidized, topical hemostasis with, 525
Chemotherapy, effects on coagulation and interactions with anticoagulants, 466
Chitin/chitosan dressings, topical hemostasis with, 526
Cilostazol (Pletal), in oral and maxillofacial surgery patients, 499
Cirrhosis, oral and maxillofacial surgery in patients with, 462–463
Clopidogrel (Plavix), in oral and maxillofacial surgery patients, 498–499

Coagulation testing, in patients undergoing oral and maxillofacial surgery, 466–467
Coagulopathy, in oral and maxillofacial surgery patients, 443–568
  administration of coagulation-altering therapy, anticoagulants, 445–447
  herbal medications and antiplatelet drugs, 444–445
  perioperative management, 447–454
  periprocedural management of patients on, 454–457
  thrombin inhibitors, 445
  thrombolytics and fibrinolytics, 445
antiplatelet medications, 497–506
  adenosine diphosphate receptor inhibitors, 498–499
  adenosine reuptake inhibitors, 499
  hemorrhagic versus thrombotic risks, 501–502
  information for surgeons, 502–503
  intravenous antiplatelets, 499–500
  phosphodiesterase inhibitors, 499
  therapy with, 500
  thromboxane/cyclooxygenase inhibitor, 497–498
  withdrawal, 500–501
blood products, 543–552
  anti-inhibitor coagulant complex, 548
  cryoprecipitate, 545–546
  Factor IX, 547–548
  Factor VIIA, 546
  Factor VIII, 547
  Factor XIII, 546–547
  Factor XIII-A subunit, 549
  fibrinogen concentrate, 548–549
  fresh frozen plasma, 545
  plasma, 545
  platelets, 544–545
  prothrombin complex concentrates, 546
  red blood cells, 543–544
  transfusion complications, 549–550
  damage control resuscitation for catastrophic bleeding, 533–568
  hemodynamic resuscitation, 556–558
  hemorrhage-associated coagulopathy, 555–556
  hemorrhagic shock, 554–555
  hemostatic resuscitation, 561–563
    acidosis, 561
    divalent catastrophic deficiency, 562
    hypothermia, 561–562
    hypoxia, 562
    minimizing ischemia-reperfusion injury, 562–563
hemophilia, 481–489
  acquired, 485–486
  congenital, 482–483
  historical perspective, 482
  inhibitors, 483–485
  management, 486–487
  overview of coagulation, 482
  surgery in patients with, 487–489
heparin and Lovenox, 507–513
contraindications, 510
dosing, 509
fondaparinux, 511
management for surgery, 511–512
monitoring, 509–510
pharmacology and pharmacokinetics, 509
reversal, 510–511
side effects, 510
uses, 509
hypercoagulable states, 491–495
diagnosis of inherited conditions, 494–495
major anticoagulant mechanisms of blood, 491–492
normal hemostasis, 491
selected conditions, 492–494
treatment, 495
interventional radiology and bleeding disorders, 533–542
angiography, 536
embolization, 536–539
endovascular techniques, 534–536
impact on oral and maxillofacial surgery, 540–541
potential complications, 539–540
platelet abnormalities, 473–480
acquired thrombocytopenias, 478–479
clinical evaluation of patients with, 475
congenital thrombocytopenias, 477–478
drug-induced antiplatelet activity and, 476–477
immune-mediated thrombocytopenias, 475–476
physiologic pathways of, 474–475
physiology of normal patients, 473–474
thrombocytosis, 479
systemic disease and bleeding disorders, 461–471
bone marrow failure, 464
coaugulation testing, 466–467
diseases affecting drug metabolism, 464–466
implications for oral and maxillofacial surgery patients, 468–469
kidney disease, 463–464
liver disease, 461–463
topical hemostatic agents, 523–532
biological hemostats, 525–526
bleeding diathesis, 524
electrical and laser hemostasis, 528–530
occlusive agents, 527
review of normal hemostasis, 523–524
scaffold/matrix agents, 524–525
stypics, 526–527
tissue adhesives, 527
tissue sealants, 527
vasoconstrictors, 527–528
warfarin and newer agents, 515–521
determining timing of anticoagulant interruption, 516
determining whether to use bridging anticoagulation, 516
direct oral anticoagulants, 516–519
estimating bleeding risk, 516
estimating thromboembolic risk, 516
warfarin, 519–520
Collagen, microfibrillar, topical hemostasis with, 525
Congenital hemophilia, in oral and maxillofacial surgery patients, 482–483
Congenital thrombocytopenias, in oral and maxillofacial surgery patients, 477–478
Coronary artery disease, oral and maxillofacial surgery in patients in antiplatelet medications for, 497–506
Coumadin. See Warfarin.
Cryoprecipitate, transfusion of, 545–546
D
Dabigatran (Pradaxa), administration in patients presenting for surgery, 446, 515–521
reversal of, 518–519
Damage control resuscitation, for catastrophic bleeding, 533–568
hemodynamic resuscitation, 556–558
hemorrhage-associated coagulopathy, 555–556
hemorrhagic shock, 554–555
hemostatic resuscitation, 558–561
fixed component ratio-directed, 558–559
goal-directed, 559–560
pharmacologic adjuncts, 560–561
homeostatic resuscitation, 561–563
acidosis, 561
divalent catastrophic deficiency, 562
hypothermia, 561–562
hypoxia, 562
minimizing ischemia-reperfusion injury, 562–563
Desirudin, administration in patients presenting for surgery, 445
Dipyridamole (Persantine), in oral and maxillofacial surgery patients, 499
Direct oral anticoagulants. See also specific agents. diseases affecting metabolism of, 464–465
in oral and maxillofacial surgery patients, 515–521
determining timing of anticoagulant interruption, 516
determining whether to use bridging anticoagulation, 516
direct oral anticoagulants, 516–519
estimating bleeding risk, 516
estimating thromboembolic risk, 516
Direct (continued)
perioperative management of patients on,
452–454
periprocedural management of patients on,
456–457
Divalent catastrophic deficiency, in catastrophic
bleeding, homeostatic resuscitation for, 562
Drug-induced antiplatelet activity, and
thrombocytopenias in oral and maxillofacial
surgery patients, 476–477

E
Edoxaban (Savaysa), administration in patients
presenting for surgery, 447
Effient. See Prasugrel.
Electrocautery, topical hemostasis with, 528
Electrosurgery, topical hemostasis with, 528
Eliquis. See Apixaban.
Embolization, in bleeding disorders, 536–539
Emergency surgery, in patients on anticoagulants,
perioperative management of, 454
Endovascular techniques, for interventional
radiology, 534–536
Epinephrine, topical hemostasis with, 527–528
Eptifibatide (Integrillin), 500

F
Factor IX, transfusion of, 547–548
Factor V Leiden, in hypercoagulable states, 491–495
Factor VIIa, transfusion of, 546
Factor VIII, transfusion of, 547
Factor XIII, transfusion of, 546–547
Factor XIII-A subunit, transfusion of, 549
Fibrinogen concentrate, transfusion of, 548–549
Fibrinolytics, administration in patients presenting for
surgery, 445
Fondaparinux (Arixtra), administration in patients
presenting for surgery, 446, 511
perioperative management of, 452
periprocedural management of, 456
Fresh frozen plasma, transfusion of, 545

G
Gelatin matrix, topical hemostasis with, 524–525
Glycoproteins lb/lIa inhibitors, 499–500
abciximab (ReoPro), 499–500
eptifibatide (Integrillin), 500
tirofiban (Aggrastat), 500

H
Hemocoagulase, topical hemostasis with, 525–526
Hemophilia, in oral and maxillofacial surgery patients,
481–489
acquired, 485–486
congenital, 482–483
historical perspective, 482
inhibitors, 483–485
management, 486–487
overview of coagulation, 482
surgery in patients with, 487–489
Hemorrhagic shock, damage control resuscitation
for, 554–555
Hemostasis, review of normal, 523–524
Hemostatic agents, topical, 523–532
biological hemostats, 525–526
antifibrinolytics, 525
naturally occurring procoagulants, 525–526
topical thrombin, 525
bleeding diathesis, 524
electrical and laser hemostasis, 528–530
electrosurgery and electrocautery, 528
lasers, 528–530
occlusive agents, 527
alkylene oxide copolymer, 527
bone wax, 527
review of normal hemostasis, 523–524
scaffold/matrix agents, 524–525
gelatin matrix, 524–525
microfibrillar collagen, 525
microporous mucopolysaccharide spheres, 525
oxidized cellulose, 525
styptics, 526–527
hydrophylic polymers with potassium salts, 526
mineral salts, 526–527
tissue sealants, 527
tissue adhesives, 527
tissue sealants, 528
vasoconstrictors, 527–528
epinephrine, 527–528
Hemostatic resuscitation, for catastrophic bleeding,
558–561
fixed component ratio-directed, 558–559
goal-directed, 559–560
pharmacologic adjuncts, 560–561
Heparin, administration in patients presenting for
surgery, 446
low-molecular-weight, 446
periprocedural management of patients on,
456
unfractionated, 446
periprocedural management of patients on,
455–456
and Lovenox in oral and maxillofacial surgery
patients, 507–513
contraindications, 510
dosing, 509
fondaparinux, 511
management for surgery, 511–512
monitoring, 509–510
pharmacology and pharmacokinetics, 509
reversal, 510–511
side effects, 510
uses, 509
Herbal medications, and antiplatelet drugs, 444–445
Hirudins, administration in patients presenting for surgery, 445
Homeostatic resuscitation, for catastrophic bleeding, 561–563
acidosis, 561
divalent catastrophic deficiency, 562
hypothermia, 561–562
hypoxia, 562
minimizing ischemia-reperfusion injury, 562–563
Hydrophilic polymers, with potassium salts, topical hemostasis with, 526
Hypercoagulable states, in oral and maxillofacial surgery patients, 491–495
diagnosis of inherited conditions, 494–495
major anticoagulant mechanisms of blood, 491–492
circulating proteins, 492
endothelial cell, 491–492
normal hemostasis, 491
selected conditions, 492–494
treatment, 495
Hypothermia, in catastrophic bleeding, homeostatic resuscitation for, 561
Hypoxia, in catastrophic bleeding, homeostatic resuscitation for, 561

I
Immune-mediated thrombocytopenias, in oral and maxillofacial surgery patients, 475–476
Immunosuppressants, effects on coagulation and interactions with anticoagulants, 466
Integrillin. See Eptifibatide.
Interventional radiology, and bleeding disorders, 533–542
angiography, 536
embolization, 536–539
endovascular techniques, 534–536
impact on oral and maxillofacial surgery, 540–541
potential complications, 539–540
Ischemia-reperfusion injury, minimizing, in resuscitation for catastrophic bleeding, 562–563

J
Jantoven. See Warfarin.

K
Kidney diseases, oral and maxillofacial surgery in patients with, 463–464

L
Lasers, topical hemostasis with, 528–530
Lepirudin, administration in patients presenting for surgery, 445
Liver diseases, oral and maxillofacial surgery in patients with, 461–463
cirrhosis, 462–463
Lovenox. See Low-molecular-weight heparin.
Low-molecular-weight heparin, in oral and maxillofacial surgery patients, 507–513
contraindications, 510
dosing, 509
fondaparinux, 511
management for surgery, 511–512
monitoring, 509–510
periprocedural management of patients on, 456
pharmacology and pharmacokinetics, 509
reversal, 510–511
side effects, 510
uses, 509

M
Marevan. See Warfarin.
Mechanical heart valves, perioperative management of patients on warfarin for, 451
Microporous mucopolysaccharide spheres, topical hemostasis with, 525
Mineral salts, topical hemostasis with, 526–527
Myocardial infarction, oral and maxillofacial surgery in patients in antiplatelet medications for, 497–506

O
Oral and maxillofacial surgery, coagulopathy in. See Coagulopathy.

P
Perioperative management, of coagulation-altering therapy, 447–454
in emergency surgery, 454
fondaparinux, 452
new oral anticoagulants, 452–454
warfarin, 448–452
Persantine. See Dipyridamole.
Phosphodiesterase inhibitors, 499
Plasma, transfusion of, 545
fresh frozen, 545
frozen within 24 hours, 545
thawed, 545
Platelet abnormalities, in oral and maxillofacial surgery patients, 473–480
acquired thrombocytopenias, 478–479
clinical evaluation of patients with, 475
Platelet (continued)
congenital thrombocytopenias, 477–478
drug-induced antiplatelet activity and, 476–477
immune-mediated thrombocytopenias, 475–476
physiologic pathways of, 474–475
physiology of normal patients, 473–474
thrombocytosis, 479
Platelet count, in preoperative assessment, 467
Platelets, transfusion of, 544–545
Plavix. See Clopidogrel.
Pletal. See Cilostazol.
Pradaxa. See Dabigatran.
Prasugrel (Effient), 499
Praxbind, reversal of direct oral anticoagulants with, 518–519
Procoagulants, naturally occurring, for topical hemostasis, 525–526
Protein C, in hypercoagulable states, 491–495
Protein S, in hypercoagulable states, 491–495
Prothrombin complex concentrates, transfusion of, 546
Prothrombin time, in preoperative assessment, 466–467
Pulmonary embolism, perioperative management of patients on warfarin for, 450–451
R
Radiology, interventional, and bleeding disorders, 533–542
angiography, 536
diagnostic evaluation, 536–539
endovascular techniques, 534–536
impact on oral and maxillofacial surgery, 540–541
potential complications, 539–540
Red blood cells, transfusion of, 543–544
Reopro. See Abciximab.
Resuscitation, damage control, for catastrophic bleeding, 533–568
hemodynamic resuscitation, 556–558
hemorrhage-associated coagulopathy, 555–556
hemorrhagic shock, 554–555
hemostatic resuscitation, 558–561
fixed component ratio-directed, 558–559
goal-directed, 559–560
pharmacologic adjuncts, 560–561
homeostatic resuscitation, 561–563
acidosis, 561
divalent catastrophic deficiency, 562
hypothermia, 561–562
hypoxia, 562
minimizing ischemia-reperfusion injury, 562–563
Reversal, of direct oral anticoagulants, 518–519
of warfarin, 519–520
Rivaroxaban (Xarelto), administration in patients presenting for surgery, 446, 515–521
reversal of, 518–519
S
Savaysa. See Edoxaban.
Scaffold/matrix agents, for topical hemostasis, 524–525
gelatin matrix, 524–525
microfibrillar collagen, 525
microporous mucopolysaccharide spheres, 525
oxidized cellulose, 525
Sealants, tissue, topical hemostasis with, 527
Styptics, for topical hemostasis, 526–527
hydrophobic polymers with potassium salts, 526
mineral salts, 526–527
T
Thrombin, topical, 525
Thrombin inhibitors, administration in patients presenting for surgery, 445
argatroban, 445
hirudins, 445
Thrombocytopenias, in oral and maxillofacial surgery patients, 473–480
acquired, 478–479
clinical evaluation of patients with, 475
congenital, 477–478
drug-induced antiplatelet activity and, 476–477
immune-mediated, 475–476
physiologic pathways of, 474–475
physiology of normal patients, 473–474
thrombocytosis, 479
Thrombocytosis, in oral and maxillofacial surgery patients, 479
Thromboelastography, in preoperative assessment, 467
Thrombolysis, administration in patients presenting for surgery, 445
Thrombophilia, in oral and maxillofacial surgery patients, 491–495
diagnosis of inherited conditions, 494–495
major anticoagulant mechanisms of blood, 491–492
circulating proteins, 492
endothelial cell, 491–492
normal hemostasis, 491
selected conditions, 492–494
treatment, 495
Thromboxane/cyclooxygenase inhibitor, in oral and maxillofacial surgery patients, 497–498
Ticagrelor (Brilinta), 499
Ticlid. See Ticlopidine.
Ticlopidine (Ticlid), 498
Tirofiban (Aggrastat), 500
Tissue adhesives, topical hemostasis with, 527
Tissue sealants, topical hemostasis with, 527
Topical hemostatic agents
  biological hemostats, 525–526
  antifibrinolytics, 525
    naturally occurring procoagulants, 525–526
    alginate dressings, 526
    chitin/chitosan dressings, 526
    hemocoagulants, 525–526
    mineral zeolite, 526
  topical thrombin, 525
  bleeding diathesis, 524
  electrical and laser hemostasis, 528–530
    electrocautery, 528
  occlusive agents, 527
    alkyene oxide copolymer, 527
  review of normal hemostasis, 523–524
  scaffold/matrix agents, 524–525
    gelatin matrix, 524–525
    microfibrillar collagen, 525
    microporous mucopolysaccharide spheres, 525
    oxidized cellulose, 525
  styptics, 526–527
    hydrophylic polymers with potassium salts, 526
    mineral salts, 526–527
  tissue adhesives, 527
  tissue sealants, 527
  vasoconstrictors, 527–528
    epinephrine, 527–528
Transfusion, of blood products, complications of, 549–550
  acute hemolytic reactions, 549
  allergic reactions, 550
  bacterial contamination and endotoxemia, 549
  nonhemolytic febrile reactions, 549
  transfusion-related acute lung injury, 549
  volume overload, 549

U
  Unfractionated heparin. See Heparin, unfractionated.

V
  Vasoconstrictors, topical hemostasis with, 527–528
  Venous thromboembolism (VTE), perioperative management of patients on warfarin for, 450–451

W
  Warfarin, administration in patients presenting for surgery, 446
    perioperative management of patients on, 446–452
    for atrial fibrillation, 448–450
    for mechanical heart valves, 451
    restarting therapy, 452
    for VTE or PE, 450–451
    periprocedural management of patients on, 456
    in oral and maxillofacial surgery patients, 515–521
      determining timing of anticoagulant interruption, 516
      determining whether to use bridging anticoagulation, 516
      estimating bleeding risk, 516
      estimating thromboembolic risk, 516
      warfarin, 519–520

X
  Xarelto. See Rivaroxiban.

Z
  Zeolite, mineral, topical hemostasis with, 526